It Is up to Novartis to Wrap up the Deal, Lek CEO Says
Ljubljana, 30 August - The value of the shares will be subject to discussions between Lek shareholders and Novartis. It depends on the shareholders' arguments and negotiating skills whether the share price will go beyond SIT 95,000/EUR 417.3 per share, CEO of Slovenian drug maker Lek, Metod Dragonja told the public TV network late on Thursday, when asked what he thought of the proposed takeover price.
The rest of this news item is available to subscribers.
The news item consists of 2.113 characters (without spaces) or 414 words words.
Buy the news item. Price: 2 tokens; on account: 0 tokens.